Fairvalue-Calculator Fairvalue-Calculator

Synmosa Biopharma Corporation (4114) Fair Value & Analysis

Healthcare · TW · Market cap 15.4B TWD

Price30.90 TWD
Fair Value26.83 TWD
Upside-13.2%
Quality81/100
Evidence: Medium Range 15.01 TWD – 37.74 TWD

Analysis

Synmosa Biopharma Corporation (4114) currently trades at 30.90 TWD, while our model-based Fair Value estimate is 26.83 TWD — implying the stock looks roughly 13.2% overvalued today. We read business quality at 81/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale retail of environmental drugs; and import and export of related businesses. The company was founded in 1959 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.